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Few clinical settings in resource-limited countries perform CD4+ T-lymphocyte counts required as a 
baseline test for antiretroviral therapy. We investigated CD4 count in newly diagnosed HIV-infected 
patients attending our treatment centre and evaluated suitability of total lymphocyte count (TLC) as a 
surrogate marker for CD4+T-lymphocyte count required as a yardstick for initiating antiretroviral 
therapy. Usefulness of TLC as a surrogate marker for  CD4+T-lymphocyte counts  <200, ≤350 and 
<500cells/µL for HIV-positive patients in our facility was evaluated by 180 pairs of TLC and CD4  counts 
from 180 newly diagnosed HIV-infected patients and results were compared by linear regression and 
Spearman’s correlation analytical tools. Approximately 72.8% of our patients were diagnosed late as 
revealed by CD4 count ≤350cells/µL. An overall good correlation was noted between TLC and CD4+T-
cell counts (r=0.65, slope=0.69), mean total lymphocyte count of 1.04 ± 0.81, 1.39 ± 1.06 and 1.57 ± 1.13 x 
10⁹/L correspond to CD4 lymphocyte counts of <200, ≤350 and < 500cells/µL respectively. When 
considering initiating HAART for HIV-infected Nigerian clients, TLC can be considered as an 
inexpensive and easily accessible surrogate marker for predicting CD4+T-lymphocyte at two clinically 
important CD4 thresholds of CD4 count of ≤350 cells/µL and <500cells/µL. 
 
Key words: CD4, total lymphocyte count, highly active antiretroviral therapy, enzyme immunoassay, HIV, 
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INTRODUCTION  
 
The CD4+T lymphocyte count is the determination of the 
concentration of CD4+ T  lymphocyte  in  the  blood.  The 
associated immune deficiency in human 
immunodeficiency virus (HIV) patients leading to infection  
 
 
 
 
 
 
 
by opportunistic pathogen is ascribed to depletion of CD4 
T-cells (Shearer, 1983). CD4 count can therefore be 
regarded as the accurate measurement of the robustness 
and functionality of the immune capability to protect the 
body against general infection. CD4+T lymphocyte cell 
depletion is one of the hallmarks of progression of HIV 
infection and a major indicator of the stage of the disease 
in HIV infected individuals (Hogg et al., 2001; Mellors et 
al., 1997; WHO, 2005). World Health Organization 
recommended that most treatment initiation decisions be 
guided by CD4 measurement and clinical staging (Balter, 
2003; Hanson et al., 1995). Previous study has shown 
good correlation between CD4 count and development of 
various complications in HIV/AIDS (Stein et al., 1992). 
Patients with low CD4+ T lymphocyte cell count have 
been reported as long-time infected patients than those 
with higher CD4 count (Hammer, 1997). It is clear that 
late starters of highly active antiretroviral therapy with 
CD4 count <200 cells/µl have significantly poor response 
to therapy and a worse prognosis when compared with 
early starters with higher CD4+ T cell count (Cheisson et 
al., 2000; Ledergerber,1999; Kilaru et al., 2004).  The 
relative ease of CD4 cell monitoring also led to its 
advocacy in treatment guidelines for determining when to 
start, stop or change antiretroviral therapy and for 
deciding when to initiate prophylaxis for opportunistic 
infections (OIS) (Arthur and Sahan, 2006).  
Retroviral disease has become a matter of relative 
chronicity in patients that have access to antiretroviral 
therapy and have benefitted greatly in marked reductions 
in morbidity and mortality. General treatment guidelines 
for the treatment of HIV-infected patients in many 
countries have adopted three approaches for the initiation 
of antiretroviral therapy. Early intervention in asymptoma-
tic patients involves the commencement of antiretroviral 
therapy once the CD4 count is less than < 500 cells/µl. A 
less intensive approach is to recommend antiretroviral 
therapy when the CD4 count falls to 350 cells/µl.  
In other countries where patients have limited financial 
resources, treatment decisions are typically delayed until 
the CD4 count becomes less than 200 cells/µl (Tarwater 
et al., 2001; BHIVA, 2000; Mellors, 1997). Recent study 
by the French researchers at the 7th International AIDS 
Society Conference on HIV Pathogenesis, Treatment and 
Prevention in Kuala Lumpur, Malaysia (Hocqueloux et al., 
2013) showed that people with HIV who start treatment 
with CD4 counts above 500, after the first phase of 
primary infection is over, are much more likely to 
experience substantial reductions in the reservoir of  HIV- 
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infected cells in their bodies, making them strong 
candidates for future research studies that seek to control 
HIV without medication. The French group found that 
people with HIV who started treatment with a CD4 cell 
count above 500 were 56 times more likely to experience 
a normalization of immune function and a reduction in 
HIV DNA to low levels when compared to people who 
started treatment at lower CD4 counts. Although it is well 
established that people who start HIV treatment with a 
CD4 count above 500 stand a better chance of achieving 
a CD4 cell count in the normal range (defined as 900 to 
1000 cells/mm
3
 according to the study), studies of people 
treated in chronic infection have not found evidence of a 
substantial reduction in HIV DNA (the reservoir of HIV 
within cells) over time. This outcome gives strong support 
to earlier interventions and showed the likely future 
direction in HIV treatment modalities. It then becomes 
very vital at every health institution involved in HIV/AIDS 
testing and treatment to establish the usefulness of total 
lymphocyte count as an alternative and inexpensive 
immunological marker for CD4 count where 
flowcytometric technique is not available. This is 
imperative not only at CD4 count threshold of < 200 and 
≤ 350 cells/µl only but also at < 500 and ≥ 500 cells/µl 
thresholds.   
Total lymphocyte count (TLC) is a derived 
immunological marker calculated from white blood cell 
count and relative lymphocyte count. For instance, if a 
patient has a total white blood cell count of 6.0 × 10⁹/L 
and relative lymphocyte count of 40% obtained from 
differential leukocyte count, total lymphocyte count of 
such patient would be 2.4 × 10⁹/L. There are series of 
controversial research outcomes over the use of TLC as 
a surrogate marker for CD4 count estimation (Anastos, 
2004; Beck et al., 1996; Gitura et al., 2007; Akinola, 
2005; Deresse and Eskindir, 2008; Chigu et al., 2006; 
Nyawira, 2011). Decisions became difficult to take as our 
health care providers insist on scientific evidence on the 
use of total lymphocyte count as an inexpensive point-of-
care alternative for absolute CD4 count. Moreover, there 
are limited data on the use of TLC as surrogate marker 
for absolute CD4+T-lymphocyte count at a CD4 threshold 
of < 500 cells/µl especially in a facility located in a rural 
and resource-limited setting in Nigeria.  
Recently published PEPFAR II goals stated that an 
estimate of 100,000 children needed to be newly initiated 
on highly active antiretroviral therapy before 2013 
(PEPFAR, 2011). In line with this, new sites have been 
established throughout Nigerian states including Ekiti.   
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Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution 
License 4.0 International License  
 
 
 
24          J. Med. Lab. Diagn. 
 
 
 
Five new sites are receiving services from our 
treatment centre across Ekiti state as a comprehensive 
HIV treatment centre owing to lack of CD4 cyflow coun-
ter. Most of those sites across the country do not have 
cyflow counter to perform routine CD4 count analysis, 
and flowcytometry remains the reference method for the 
performance of CD4 count (Mellors et al., 1997). Even in 
centers where CD4 equipment are available, treatment 
decisions are sometimes delayed owing to varying fac-
tors ranging from proximity of the patients to testing and 
treatment sites, equipment breakdown, non-availability of 
reagents on consistent basis to late access to service 
engineers.  
These therefore necessitate the need for the evaluation 
and validation of the correlation of TLC with CD4 count 
and its usefulness as a surrogate marker for CD4 count 
estimation. This is the first time it will be determined in 
this health institution in Ekiti state, South-West Nigeria. 
To the best of our knowledge, no research study in Ekiti 
state has determined the correlation between CD4 and 
total lymphocyte count to include CD4 count threshold of 
< 500 cells/µl but past studies have concentrated on 
correlations between absolute CD4 count and TLC at < 
200 and < 350 cells/µl thresholds.  
This study was carried out to determine at what stage 
of the disease HIV infected persons presented to our 
treatment facility, and to have comparison with our pre-
vious findings here and in other centres. Moreover, the 
total lymphocyte count as at the time of presentation will 
also determined and correlated with the CD4 count at dif-
ferent CD4 thresholds including < 500 cells/µl to establish 
its diagnostic utility as a surrogate marker for CD4 count.  
The goal is to facilitate earlier treatment in newly 
diagnosed HIV patients based on total lymphocyte count 
results obtained from HIV positive samples at attached 
centres rather than travelling, in some cases, over 50 km 
distance to have CD4 count result done and asking the 
physicians to wait for results from testing sites. Delay as-
sociated with such old arrangement has been responsible 
for delay in initiation of highly active antiretroviral therapy, 
loss of follow-up, non-compliance to antiretroviral the-
rapy, poor prognosis, immunologic failure and increased 
morbidity and mortality among HIV-infected patients.  
 
 
METHODS      
 
Study location 
 
This study was carried out at the Haematology department of the 
Federal Medical Centre (FMC); Ido Ekiti, Nigeria over a period of 
three years. FMC is located in Ido Ekiti, the principal town in Ido Osi 
Local Government Area of Ekiti State with an estimated population 
of 107,000. It is geographically located in the northern  part  of  Ekiti 
State which covers an estimated total area of 6353 km², 2,453 square 
mile and an estimated population  of  2,737,186,  where  the  routes  
 
 
 
 
from Kwara and Osun states converge. FMC, Ido Ekiti was up-
graded in 2006 to serve as a centre for HIV/AIDS referral, diagnosis 
and treatment in Ekiti State and serving five contiguous states. The 
Centre has since that time been offering free diagnosis and 
antiretroviral therapy. 
 
 
Study design 
 
This study consisted of enumeration of total and CD4 T-helper 
lymphocyte counts of 180 HIV- infected subjects at baseline before 
initiation of highly active antiretroviral therapy (HAART). A model 
linear regression analysis was applied to the data and the sensiti-
vity and specificity of the World Health Organization recommended 
TLC thresholds corresponding to CD4 count <200, ≤350 and <500 
cells/µL were determined. 
 
 
HIV counseling and testing 
 
Early and accurate diagnosis of human immunodeficiency virus 
(HIV) in retroviral patients is sine quanon to successful manage-
ment, good prognosis, effective follow-up and increased reduction 
of morbidity and mortality due to opportunistic infections among 
infected patients. All enrolled subjects were newly diagnosed for 
HIV at our HIV counseling and testing (HCT) site and PEPFAR-
Supported laboratory at the Haematology Department according to 
the Centre for Disease Control and Prevention serial Algorithm II 
guidelines. We performed HIV testing using two rapid enzyme 
immunoassay (EIA) techniques. Whole blood samples obtained by 
capillary puncture or plasma samples separated from 4 millilitres of 
whole blood collected into K2EDTA spray-dried collection tubes 
were used for the procedures and the tests were performed accor-
ding to CDC-UMD HIV rapid testing serial algorithm II guideline. We 
first used Determine kit, an immunochromatographic technique 
(Abbot Laboratories, Abbot Park, USA). Negative result by Deter-
mine ended testing but research patients were requested to repeat 
test 1 month to confirm negative results. Positive results observed 
were repeated with Unigold Kit (Trinity Biotech, Wicklow, Ireland).  
Discordant results were first repeated by senior research 
counsellor and tester to ascertain true inconclusive results and 
finally tested with the tie-breaker kit-Stat-Pak (Chembio Medford, 
NY, USA), an immunoconcentration technique. Final test results 
were considered positive/negative on the basis of the tie-breaker 
result and corresponding similar result from one of previous test 
procedures (WHO, 2007). Similar results were obtained from 
Genscreen HIV 1&2 kits (Biorad, France). The rapid HIV screening 
technique was an enzyme immunoassay based on the detection of 
antibodies to HIV in the patients’ sera or plasma. The Genscreen 
ULTRA HIV Ag-Ab is an enzyme immunoassay based on the 
principle of sandwich technique for the detection of HIV antigen and 
of the various antibodies associated with HIV-1 and/or HIV-2 virus 
in human serum or plasma. Diagnostic techniques/algorithm was 
quality controlled using oneworldAccuracy HIV samples with 
already known positive and negative HIV results. Patients with two 
concurrent positive HIV results and who were repeatedly reactive 
were enrolled in the study.  
 
 
Blood sample requirements, CD4 count and complete blood 
count analyses 
 
Patients already confirmed HIV positive had their blood samples 
taken (following informed consent as part  of  the  ethical  guideline) 
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Table 1. The Overall data showing the Mean age, CD4 and TLC, the correlation coefficient, slope and p-value of HIV infected patients 
 
Age CD4 count (Cells/µL) Total lymphocyte count (x 10⁹/L) r Slope p-value 
37.89±10.47 250.81 ±226.59 1.79±1.43 0.65** 0.69** 0.01 
 
Correlation is significant at p=0.004.  
 
 
Table 2. Correlation of CD4 T-lymphocytes and total lymphocytes count of HIV-infected patients 
 
CD4 Count 
Thresholds (Cells/µl) 
CD4 Count 
(Cells/µL) 
Total lymphocyte count 
(× 10⁹/L) 
r Slope P -value 
<200 82.96±57.03 1.04±0.81 0.30 0.46 <0.05 
≤350 140.23±104.05 1.39±1.06 0.55** 0.64 <0.01 
<500 188.22±144.80 1.57±1.13 0.58** 0.68 <0.05 
≥500 687.86±224.34 3.29±2.27 0.58* -0.013 >0.05 
 
**Correlation is significant at p=0.004 
 
 
for baseline CD4 count and total lymphocyte count estimation at 
initial visit as part of routine work up to access their baseline status 
and eligibility for antiretroviral therapy. CD4 cell count and complete 
blood count (CBC) were determined using a freshly collected blood 
sample drawn into two separate 4 ml spray-dried dipotassium 
ethylenediaminetetraacetic acid (K₂EDTA) anticoagulant bottles and 
processed within 4 hours of venepuncture.  Samples for CD4 count 
were prepared and run on the Partec cyflow counter (Partec flow 
cytometer, GMBH, Germany) according to the manufacturer’s 
instructions.  
 
 
Principle of flow cytometry for cd4 count 
 
The cyflow counter operation is based on the simultaneous 
measurement of multiple physical characteristics of CD4 T-cells in a 
single file as it flows through the cyflow counter. The counter 
separated the CD4+ T cell from the monocytes-CD4 bearing cells 
and noise using a gating system. We prepared the samples and 
analyzed CD4 count according to the manufacturer’s instructions. 
 
 
CBC analysis and TLC calculation. 
 
The CBC samples were run directly on Sysmex KX-21N three-part 
differential haematology analyzer (Sysmex Corporation, Kobe, 
Japan). TLC was calculated from white blood cell count and relative 
lymphocyte count. Sysmex KX-21N is a three-part open tube 
differential haematology analyzer according to manufacturer’s 
instructions.  
 
 
Statistical analysis 
 
Data were computed using SPSS statistical software (Statistical 
Package for Social Sciences Inc, Chicago IL), version 17. The 
summary of the continuous variables were presented as means and 
standard deviation using one sample t-test. Correlation data 
obtained with the surrogate marker (total lymphocyte count) were 
compared to the reference flow cytometric CD4 count and the 
correlation coefficient was calculated. The degree of correlation 
between the reference CD4 count and total lymphocyte count was 
further established using bivariate Spearman’s analytical tool.  We 
also determined the proportion of results classified by the total 
lymphocyte counts at various CD4 T-cell count thresholds relevant 
for clinical management of HIV-infected patients (< 200, ≤350 and < 
500 cells/µL). A p-value =0.05 was considered significant for all 
statistical comparison. 
 
 
RESULTS      
 
A total of 180 HIV research patients comprising 54 males 
and 126 females aged 20-80 years, mean age 
37.89±10.47 years were involved in the study. 89 of the 
patients who are approximately 49.4% were asymptoma-
tic HIV-infected patients. The overall mean baseline CD4 
count and total lymphocyte count were 250.81±226.59 
and 1.79±1.43 × 10⁹/L, respectively as shown in Table 1. 
Of the 180 research patients, 51.67, 72.78 and 87.22% 
had CD4 count values of <200, ≤350 and <500, respec-
tively. The remaining 12.78% had CD4 count of ≥500 
cells/µL. The overall correlation coefficient between CD4 
and total lymphocyte count of HIV-infected subjects was 
modest (r=0.65**, p< 0.01).  Table 2 showed the com-
parison of correlation between CD4 and total lymphocyte 
counts based on CD4 T-lymphocyte count thresholds 
(<200, ≤350, <500 and >500 cells/µL) relevant to clinical 
management of HIV-infected Nigerians.     
The correlation between total lymphocyte count and 
CD4 count was modest at a CD4 count threshold of ≤350 
cells/µL (r=0.55**, p < 0.01) compared to a low 
correlation at a CD4 threshold of < 200cells/µL (0.30, 
p<0.05) and slightly higher correlation at a CD4 threshold 
of <500 and ≥500 cells/µL (r=0.58, p<0.01). The slope 
was further determined to establish the degree of 
association   between  total  lymphocyte  count  and  CD4 
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count thresholds. The slopes for CD4 count thresholds 
<200, ≤350, <500 cells/µL were 0.46, 0.64, 0.68, respec-
tively at p<0.05. CD4 count threshold of >500 cells/µL 
showed negative association at p> 0.05, p=0.95 
specifically. Total lymphocyte count of 1.04 ± 0.81, 1.39 ± 
1.06 and 1.57 ± 1.13 × 10⁹/L correspond to CD4 
lymphocyte counts of <200, ≤350 and <500 cells/µL, 
respectively.   
 
 
DISCUSSION 
 
With the current trend in the clinical management of 
retroviral patients, the use of highly active antiretroviral 
therapy (HAART) has brought a panoramic change of 
positive impact in the treatment of HIV-infected patients. 
In fact, HIV patients live relatively normal lives as non-
infected subjects when diagnosed early and aggressive 
interventions are adopted. However, in many resource-
poor countries, most facilities do not have cyflow counter 
for the performance of CD4 count analysis required for 
the initiation of antiretroviral therapy. Amazingly, in Sub-
Saharan Africa where nearly 24 million people are living 
with HIV, less than 8% have access to HAART partly due 
to lack of access to CD4 count test. (WHO, 2002). In this 
study, we have evaluated the relevance of TLC as a 
readily accessible and alternative immunological marker 
for CD4 count in determining the optimal time to initiate 
highly active antiretroviral therapy in HIV-infected 
Nigerians especially those presenting late to testing and 
treatment centres. 
More than 50% (51.7%) of patients enrolled in this 
study had CD4 count <200cells/µL and 57 (61.3%) of 
these had CD4 count less than 100cells/µL at presenta-
tion. 72.8% had CD4 count ≤350cells/µL. The World 
Health Organization (Nyawira et al., 2011) recommended 
the following parameters for initiating antiretroviral 
therapy:  
 
1. Initiate ART for all patients with CD4 Count ˂200 
cells/µl regardless of clinical stage. 
2. Consider ART for all patients with stage I and II 
disease and CD4 count ≤350 cells/µl. Treatment should 
be initiated before CD4 count drops below 200 cells/µl. 
3. Initiate ART for patients with stage III disease and CD4 
count ≤350 cells/µl. 
4. Initiate ART for patients with stage IV disease 
regardless of CD4 count. 
We inferred that there was late diagnosis of HIV in the 
patients attending our treatment centre which is similar to 
findings by Kilaru and Co-workers (1997) in Barbados 
and Guarner and his group (1996) in Mexico. It is 
interesting to note that this study showed 13.4% cut in the 
 
 
 
 
overall previous findings of 86.2% among enrolled 
patients  having a relatively advanced disease as 
reflected by their CD4 + cell count of <350 cells/µL in 
2009. Of relevant interest is also the fact that while 65.5% 
of the study population in 2009 had CD4+ T-lymphocyte 
cell count of <200 cells/µL, the present study showed that 
61.3% had CD4+ cell count of < 200cells/µL, represen-
ting a concomitant cut of 4.2% (Ajayi et al., 2009). The 
observed difference between the present outcomes and 
Ajayi and his group’s findings at this health care facility 
was due to improved clinical setting (multiple testing 
sites)approach, trained counselors and testers, more 
aggressive ‘Know your HIV status’ campaign and policy 
formulations on reduction of discrimination and stig-
matization. The World Health Organization recommended 
that in treatment centres where there is no facility for 
performing absolute CD4 count test, clinicians need not 
wait until CD4 counters are available but total lymphocyte 
counts of <1200 and <1,500 µL corresponding to CD4 
count of <200 and <350 cells/µL  should be used as a 
surrogate marker.  In this research study, we observed a 
modest overall correlation coefficient of r= 0.65 (p < 0.01) 
between paired CD4 and total lymphocyte counts of 180 
HIV-infected Nigerians in Ekiti, South West, Nigeria. This 
value correlates well with that of Beck and his colleagues 
(1996) (r=0.64) obtained from a study involving 1535 
asymptomatic HIV-infected patients in the United 
Kingdom. While it is slightly lower than that obtained from 
a South African study in a larger population (n=2774) of 
HIV-infected patients (r=0.70) (van Der Ryst et al., 1998) 
it is higher than that obtained from similar studies 
involving 100 and 32 HIV- infected Nigerians with 
correlation coefficients of r=0.51 and 0.25 respectively 
(Akanmu et al., 2001; Erhabor et al., 2006)). Our results 
and those of previous studies showed that the higher the 
population of asymptomatic patients involved in the 
study, and early antiretroviral therapy intervention 
decision adopted, the better the correlation.  
Comparison of correlations between CD4 and total 
lymphocyte count at different CD4 count thresholds 
showed a correlation coefficient of r= 0.30, slope 0.46; 
0.55,**slope 0.64 and 0.58,**slope 0.68 for CD4 count 
<200, ≤350 and <500 cells/µL respectively (p < 0.05).  
Mean total lymphocyte counts of 1.04 ± 0.81, 1.39 ± 
1.06 and 1.57 ± 1.13 × 10⁹/L correspond to CD4 
lymphocyte counts of <200, ≤350 and <500 cells/µL, 
respectively. TLC is more positively correlated with CD4 
count ≤350 and ≤500 cells/µL than <200 threshold. We 
inferred that TLC does not accurately predict correspond-
ding CD4 count values in clients being severely immuno-
suppressed as at presentation to the HIV clinic.       
There was a negative correlation between TLC and 
CD4  count  ≥  500  (r=0.68,  slope= -0.013,  p=0.95).  The 
 
 
 
 
 
 
 
cause of this negative slope was unclear but we assume 
that a lower population of patients (15%) with CD4 count 
of ≥ 500 cells involved in the study are responsible. If a 
study on evaluation of TLC as a suitable substitute for 
CD4 count at a CD4 count threshold of ≥500 cells/µL 
involves a higher population of CD4 count-TLC pair, a 
better picture may be obtained.  
 
 
Conclusion 
 
When considering initiating highly active antiretroviral 
therapy in HIV-infected patients, our findings of overall 
modest correlation of r=0.65 and slope=0.69 (p=0.004) 
between total and CD4+ T-lymphocyte count has shown 
that total lymphocyte count can be used as an alternative 
inexpensive and readily available surrogate marker at two 
clinically significant CD4 thresholds of ≤ 350 and < 500 
cells/µL. It must be used in conjunction with the clinical 
status and WHO clinical staging system in determining 
the prognosis and the optimal time to initiate HAART in 
resource-poor settings without CD4 count facility. The 
findings of a cut of 13.4% in the overall findings of our 
patients presenting with relatively advanced disease as at 
diagnosis (CD4 count <350cells/µL) in 2009 and 
concomitant cut of 4.2% (CD4 < 200 cells/µL) showed a 
working system. A  more aggressive campaign and public 
enlightenment on, ‘Know your HIV status’ in Ekiti commu-
nities and neighbouring states where patients come to 
our treatment facility to access care, evidently, will further 
lead to dramatic reduction in late diagnosis of HIV, 
hence, improve TLC diagnostic utility as a surrogate 
marker for CD4+ cell count.  
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